GARDASIL

GARDASIL Uses, Dosage, Side Effects, Food Interaction and all others data.

Each dose (0.5 ml) of vaccine contains-

Human papillomavirus type 16 L1 protein 20 mcgHuman papillomavirus type 18 L1 protein 20 mcg.Human Papillomavirus (HPV) type 16 and 18 cause about 70% of cervical cancer. HPV bivalent (types 16 and 18) vaccine is a non-infectious vaccine produced by recombinant technology, which contains virus-like particles (VLP) of the major capsid LI protein of oncogenic HPV types 16 and 18. Efficacy of vaccine may be mediated by the production of IgG neutralizing antibodies against the HPV-L1 capsid proteins.

Humanpapillomavirustype16L1protein20mcgHumanpapillomavirustype18L1protein20mcg.HumanPapillomavirus(HPV)type16and18causeabout70%ofcervicalcancer.HPVbivalent(types16and18)vaccineisanon-infectiousvaccineproducedbyrecombinanttechnology,whichcontainsvirus-likeparticles(VLP)ofthemajorcapsidLIproteinofoncogenicHPVtypes16and18.EfficacyofvaccinemaybemediatedbytheproductionofIgGneutralizingantibodiesagainsttheHPV-L1capsidproteins.

GARDASIL
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	GARDASIL
Generic	Human Papillomavirus Vaccine (Types 16 + 18)
Weight	quadrivalent,
Type	Injection, Intramuscular, Suspension, Intramuscular Suspension, Hpv
Therapeutic Class	Vaccines, Anti-sera & Immunoglobulin
Manufacturer	Merck Sharp & Dohme (uk) Limited, Obs
Available Country	United Kingdom, Pakistan, Canada, United States,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Papillomavirus vaccine is used for females from 9 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous cell carcinoma and adenocarcinoma) caused by oncogenic human papillomaviruses (HPV).

Dosage

GARDASIL dosage

Intramuscular-

Adult: Females 10-25 yr (or between 10-45 yr in some countries): 3 doses of 0.5 ml each given at 0,1 and 6 mth, preferably administered into deltoid muscle.
Child: Not recommended for use in girls beiow 9 yr of age.

Side Effects

Injection site pain, erythema, and inflammation Fatigue, Headache, Myalgia, GI symptoms, Arthralgia

Precaution

Observe patient for 15 min after admin as syncope, sometimes accompanied by transient tonic clonic movements and other seizure-like activity may occur during recovery. Caution in patients with thrombocytopenia or other coagulation disorders as IM admin can cause bleeding. Not to be administered by IV, SC, or intradermal route. Immunocompromised individuals may have diminished immune response to the vaccine. As vaccination will not provide protection against every HPV infection or existing HPV infections, routine cervical screening should still be performed. Not recommended for use during pregnancy; caution in lactation.

Interaction

Immunosuppressive therapies e.g. irradiation, cytotoxic drugs and corticorsteroids may reduce a patient's immune response to the vaccine.

Pregnancy & Breastfeeding use

Pregnancy Category- B. Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation: Unknown whether distributed in breast milk